Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:GMTX NASDAQ:NAMS NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$34.00+1.0%$25.22$12.21▼$35.77$942.10M-0.18588,150 shs266,826 shsGMTXGemini Therapeutics$87.22+1.2%$65.33$1.16▼$14.10$3.78B-0.12189,291 shs983,446 shsNAMSNewAmsterdam Pharma$36.28+3.7%$28.73$14.06▼$41.47$3.94B0.021.38 million shs1.05 million shsVCELVericel$35.99-1.2%$33.68$29.24▼$63.00$1.84B1.39644,103 shs499,139 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-1.35%-1.87%+57.24%+24.68%-4.27%GMTXGemini Therapeutics-1.15%+18.04%+41.75%+41.40%+69.23%NAMSNewAmsterdam Pharma-4.06%-13.47%+29.39%+49.64%+84.99%VCELVericel-0.05%+8.45%+14.52%-8.28%-12.91%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$34.00+1.0%$25.22$12.21▼$35.77$942.10M-0.18588,150 shs266,826 shsGMTXGemini Therapeutics$87.22+1.2%$65.33$1.16▼$14.10$3.78B-0.12189,291 shs983,446 shsNAMSNewAmsterdam Pharma$36.28+3.7%$28.73$14.06▼$41.47$3.94B0.021.38 million shs1.05 million shsVCELVericel$35.99-1.2%$33.68$29.24▼$63.00$1.84B1.39644,103 shs499,139 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-1.35%-1.87%+57.24%+24.68%-4.27%GMTXGemini Therapeutics-1.15%+18.04%+41.75%+41.40%+69.23%NAMSNewAmsterdam Pharma-4.06%-13.47%+29.39%+49.64%+84.99%VCELVericel-0.05%+8.45%+14.52%-8.28%-12.91%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.67Moderate Buy$54.7861.11% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/ANAMSNewAmsterdam Pharma 2.70Moderate Buy$43.2019.07% UpsideVCELVericel 2.71Moderate Buy$58.4062.27% UpsideCurrent Analyst Ratings BreakdownLatest ANAB, GMTX, NAMS, and VCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/20/2025NAMSNewAmsterdam PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$52.0010/20/2025NAMSNewAmsterdam PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$52.0010/17/2025NAMSNewAmsterdam PharmaCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $50.0010/15/2025VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$46.00 ➝ $41.0010/15/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$45.00 ➝ $70.0010/14/2025VCELVericelZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/13/2025ANABAnaptysBioBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$78.0010/13/2025ANABAnaptysBioBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$78.0010/8/2025ANABAnaptysBioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NAMSNewAmsterdam PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VCELVericelWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$91.28M10.43N/AN/A$2.33 per share14.59GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/ANAMSNewAmsterdam Pharma$45.56M89.69N/AN/A$8.20 per share4.42VCELVericel$237.22M7.66$0.31 per share116.58$5.92 per share6.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$145.23M-$4.48N/AN/AN/A-107.66%-366.98%-30.58%11/4/2025 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/ANAMSNewAmsterdam Pharma-$241.60M-$1.62N/AN/AN/A-259.07%-27.27%-25.00%11/5/2025 (Estimated)VCELVericel$10.36M$0.12299.9481.80N/A2.85%2.47%1.69%11/6/2025 (Estimated)Latest ANAB, GMTX, NAMS, and VCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025VCELVericel-$0.02N/AN/AN/A$64.57 millionN/A11/5/2025Q3 2025NAMSNewAmsterdam Pharma-$0.41N/AN/AN/A$4.54 millionN/A11/4/2025Q3 2025ANABAnaptysBio-$1.32N/AN/AN/A$15.83 millionN/A8/6/2025Q2 2025ANABAnaptysBio-$1.50-$1.34+$0.16-$1.34$11.55 million$22.26 million8/6/2025Q2 2025NAMSNewAmsterdam Pharma-$0.52-$0.15+$0.37-$0.15$1.44 million$19.15 million7/31/2025Q2 2025VCELVericel-$0.04-$0.01+$0.03-$0.01$64.61 million$63.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A8.228.22GMTXGemini TherapeuticsN/A71.4971.49NAMSNewAmsterdam PharmaN/A21.0821.08VCELVericelN/A4.974.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/AGMTXGemini Therapeutics75.42%NAMSNewAmsterdam Pharma89.89%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%GMTXGemini Therapeutics12.90%NAMSNewAmsterdam Pharma20.84%VCELVericel5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10028.00 million18.62 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableNAMSNewAmsterdam Pharma4112.63 million89.16 millionOptionableVCELVericel30050.46 million47.84 millionOptionableANAB, GMTX, NAMS, and VCEL HeadlinesRecent News About These CompaniesVericel to Report Third-Quarter 2025 Financial Results on November 6, 20253 hours ago | markets.businessinsider.comHere’s Why Vericel Corporation (VCEL) Underperformed in Q3October 22 at 10:34 PM | msn.comVericel Corporation $VCEL Shares Purchased by Mutual of America Capital Management LLCOctober 21 at 4:40 AM | marketbeat.comTruist Lowers PT on Vericel Corporation (VCEL) to $41 From $46October 20 at 11:30 PM | insidermonkey.comConestoga Capital Advisors LLC Buys 401,990 Shares of Vericel Corporation $VCELOctober 20 at 3:33 AM | marketbeat.comWilliam Blair Investment Management LLC Sells 123,021 Shares of Vericel Corporation $VCELOctober 19, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Trading Up 5.6% - Here's What HappenedOctober 17, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Upgraded by Zacks Research to "Strong-Buy" RatingOctober 16, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Acquires 610,045 Shares of Vericel Corporation $VCELOctober 16, 2025 | marketbeat.comAberdeen Group plc Buys Shares of 209,217 Vericel Corporation $VCELOctober 16, 2025 | marketbeat.comVericel price target lowered to $41 from $46 at TruistOctober 16, 2025 | msn.comTruist Securities Maintains Vericel (VCEL) Buy RecommendationOctober 16, 2025 | msn.comLeerink Partnrs Has Pessimistic View of Vericel Q4 EarningsOctober 15, 2025 | marketbeat.comVericel Corporation (NASDAQ:VCEL) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 15, 2025 | americanbankingnews.comVericel Corporation (NASDAQ:VCEL) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 10, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Receives "Sell (D+)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comVericel Corporation $VCEL Shares Purchased by PFG Investments LLCOctober 4, 2025 | marketbeat.comCanaccord Genuity Keeps Their Buy Rating on Vericel (VCEL)September 26, 2025 | theglobeandmail.comVericel Corporation $VCEL Shares Acquired by Congress Asset Management Co.September 26, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Hits New 12-Month Low - Time to Sell?September 25, 2025 | marketbeat.comKopp Family Office LLC Sells 8,554 Shares of Vericel Corporation $VCELSeptember 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANAB, GMTX, NAMS, and VCEL Company DescriptionsAnaptysBio NASDAQ:ANAB$34.00 +0.35 (+1.04%) Closing price 04:00 PM EasternExtended Trading$34.00 0.00 (0.00%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Gemini Therapeutics NASDAQ:GMTX$87.22 +1.05 (+1.22%) As of 10/22/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.NewAmsterdam Pharma NASDAQ:NAMS$36.28 +1.28 (+3.66%) Closing price 04:00 PM EasternExtended Trading$36.28 0.00 (0.00%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Vericel NASDAQ:VCEL$35.99 -0.44 (-1.21%) Closing price 04:00 PM EasternExtended Trading$35.99 +0.00 (+0.01%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
